Waters Achieves FDA 510(k) Clearance for Ready-to-Use Flow Cytometry Clinical Tests for Leukemia and Lymphoma
Citigroup Maintains Buy on Waters, Raises Price Target to $536
JP Morgan Maintains Neutral on Waters, Raises Price Target to $470
TD Cowen Maintains Buy on Waters, Raises Price Target to $530
Barclays Maintains Overweight on Waters, Raises Price Target to $530
RBC Capital Maintains Outperform on Waters, Raises Price Target to $525
Waters Q3 Earnings Call Highlights
Keybanc Maintains Overweight on Waters, Raises Price Target to $500
Waters (WAT) Stock Could Be 27% Overvalued Despite Raised Guidance
Waters Corp (WAT) Q3 2026 Earnings Call Highlights: Raised Guidance, 21% EPS Growth and a ...
Is Waters (WAT) Fully Priced As Mixed Earnings Reset Its Valuation Story?
Waters Corporation Q3 2026 Earnings Call Summary
Earnings Beat Might Change The Case For Investing In Waters Stock (WAT)
Waters Corporation Reports Third Quarter 2026 Financial Results
Waters CEO Says AI Is Already Fueling Lab Demand As Drugmakers Race to Accelerate Discovery
Waters Corporation Raises 2026 Guidance as Q3 Revenue Surges 121% to $1.77 Billion
Waters (WAT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Waters Corp (NYSE:WAT) Q3 2026 In Line as Investors Eye 2027 Growth and MOBILion Acquisition
Waters Corporation (WAT) Q3 2026 Earnings Call Transcript
Waters: Q3 Earnings Snapshot
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.